MLAB Mesa Laboratories
- 118.110
- +1.750+1.50%
Mesa Laboratories News
When Should You Buy Mesa Laboratories, Inc. (NASDAQ:MLAB)?
While Mesa Laboratories, Inc. (NASDAQ:MLAB) might not have the largest market cap around , it led the NASDAQGS gainers with a relatively large price hike in the past couple of weeks. Shareholder
Royce Micro-Cap Trust (NYSE: RMT) as of Mar 31, 2024
NEW YORK, April 26, 2024 /PRNewswire/ -- Average weekly trading volume of approximately 538,245 shares Fund's adviser has more than 50 years of small- and micro-cap investment experience CLOSING
25 GDP-sensitive Small-Cap Stocks With Low Refinancing Risk - BofA
Mesa Laboratories Enhances Financial Structure and Reduces Debt
MESA LABS ANNOUNCES AMENDMENT TO CREDIT FACILITY AND REPURCHASE OF SENIOR CONVERTIBLE NOTES
Lakewood, Colo., April 08, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced the closing of its Amended and Restated Credit Agreem
Best Value Stocks to Buy for April 8th
Mesa Laboratories To Go Ex-Dividend On May 31st, 2024 With 0.16 USD Dividend Per Share
April 6th - $Mesa Laboratories(MLAB.US)$ is trading ex-dividend on May 31st, 2024. Shareholders of record on May 31st, 2024 will receive 0.16 USD dividend per share on June 14th, 2024. The ex-divi
Mesa Laboratories Maintains Quarterly Dividend of $0.16
MESA LABS DECLARES QUARTERLY DIVIDEND
LAKEWOOD, Colo., April 04, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa" or the "Company") today announced that its Board of Directors has declared a regular quarterly dividend of
Mesa Labs Is Maintained at Outperform by Evercore ISI Group
Mesa Labs Is Maintained at Outperform by Evercore ISI Group
Express News | Evercore ISI Group Maintains Outperform on Mesa Laboratories, Raises Price Target to $130
Mesa Laboratories Shares Sink 8% as It Sees $271M Non-Cash Impairment Losses in Q4
Mesa Laboratories expects to record non-cash impairment losses of about $271 million during the fourth quarter. The life science tools manufacturer said the losses, related to its cli
Mesa Laboratories, Inc.: Expect to Record Non-Cash Impairment Losses Related to Clinical Genomics and Biopharmaceutical Development Divisions of About $271M During 4Q FY24 >MLAB
Mesa Laboratories, Inc.: Expect to Record Non-Cash Impairment Losses Related to Clinical Genomics and Biopharmaceutical Development Divisions of About $271M During 4Q FY24 >MLAB
Mesa Laboratories, Inc. to Announce Unaudited Fourth Quarter and Full Fiscal Year 2024 Results on May 24, 2024
Mesa Labs Releases Second Annual Responsible Business Program Brochure
LAKEWOOD, Colo, March 15, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB, "Mesa" "we" "our" or the "Company")), a global leader in the design and manufacture of life science tools and critical quality
Shareholders in Mesa Laboratories (NASDAQ:MLAB) Have Lost 60%, as Stock Drops 12% This Past Week
If you love investing in stocks you're bound to buy some losers. Long term Mesa Laboratories, Inc. (NASDAQ:MLAB) shareholders know that all too well, since the share price is down considerably over t
Mesa Laboratories, Inc. (NASDAQ:MLAB) Shares Could Be 39% Below Their Intrinsic Value Estimate
Results: Mesa Laboratories, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
Mesa Laboratories Non-GAAP EPS of $2.02 Beats by $0.32, Revenue of $53.47M Misses by $1.13M
Press Release: Mesa Labs Announces Third Quarter Results
Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its third fiscal quarter ("3Q24") ended December 31, 2023.
Analysis
Price Target
No Data
